Encapsulation of Nutraceutical Ingredients in Liposomes and Their Potential for Cancer Treatment

Nutrition and Cancer

Volumn 70, Issue 8, 2018, Pages 1184-1198

  Dutta, Sayantani ^a   Moses, Jeyan Arthur ^a   Anandharamakrishnan, C ^a  

^a INDIAN INSTITUTE OF FOOD PROCESSING TECHNOLOGY   (India)

Author keywords

[No Author keywords available]

Indexed keywords

BERBERINE; BETA CRYPTOXANTHIN; BETA GLUCAN; CROCIN; CURCUMIN; CYANIDIN 3 GLUCOSIDE; EPIGALLOCATECHIN GALLATE; FISETIN; GENISTEIN; LIPOSOME; MAGNETOLIPOSOME; NUTRACEUTICAL; RESVERATROL; STEROL DERIVATIVE; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; CAROTENOID; FLAVONOID;

CANCER CELL; CANCER THERAPY; COLORECTAL CANCER; DRUG EFFECT; DRUG EFFICACY; ENCAPSULATION; HUMAN; LIPOSOMAL DELIVERY; LYMPHOMA; MEDICINAL MUSHROOM; MULTIDRUG RESISTANCE; NONHUMAN; PANCREAS CARCINOMA; PROSTATE CANCER; REVIEW; SQUAMOUS CELL CARCINOMA; UTERINE CERVIX CANCER; ANIMAL; CHEMISTRY; DIETARY SUPPLEMENT; FEMALE; MALE; NEOPLASM; PATHOLOGY;

ANIMALS; ANTINEOPLASTIC AGENTS; BERBERINE; BETA-CRYPTOXANTHIN; CAROTENOIDS; CURCUMIN; DIETARY SUPPLEMENTS; FEMALE; FLAVONOIDS; GENISTEIN; HUMANS; LIPOSOMES; MALE; NEOPLASMS; RESVERATROL;

EID: 85064083277     PISSN: 01635581     EISSN: 15327914     Source Type: Journal    
DOI: 10.1080/01635581.2018.1557212     Document Type: Review

References (69)

1. Badawi AM, : Important Facts about Cancer Prevention. Victoria, Canada: Trafford Publishing, 2012.
2. Kandile NG, : Nanotechnology and cancer prevention, detection and treatment, In: Important Facts about Cancer Prevention. Victoria, Canada: Trafford Publishing, 2012.
3. Shukla Y, and George J, : Combinatorial strategies employing nutraceuticals for cancer development. Ann N Y Acad Sci 1229, 162–175, 2011.
4. Santos IS, Ponte BM, Boonme P, Silva AM, and Souto EB, : Nanoencapsulation of polyphenols for protective effect against colon–rectal cancer. Biotechnol Adv 31, 514–523, 2013.
5. Mehta RG, Murillo G, Naithani R, and Peng X, : Cancer chemoprevention by natural products: How far have we come? Pharm Res 27, 950–961, 2010.
6. Arora D, and Jaglan S, : Nanocarriers based delivery of nutraceuticals for cancer prevention and treatment: a review of recent research developments. Trends Food Sci Technol 54, 114–126, 2016.
7. Mozafari M, and Mortazavi S, : Nanoliposomes: From Fundamentals to Recent Developments. Victoria, Canada: Trafford Publishing, 2005.
8. Riaz M, : Liposomes preparation methods. Pak J Pharm Sci 9, 65–77, 1996.
9. Aadinath W, Bhushani A, and Anandharamakrishnan C, : Synergistic radical scavenging potency of curcumin-in-β-cyclodextrin-in-nanomagnetoliposomes. Mater Sci Eng C Mater Biol Appl 64, 293–302, 2016.
10. Thangapazham RL, Puri A, Tele S, Blumenthal R, and Maheshwari RK, : Evaluation of a nanotechnology-based carrier for delivery of curcumin in prostate cancer cells. Int J Oncol 32, 1119–1123, 2008.
11. Catania A, Barrajón-Catalán E, Nicolosi S, Cicirata F, and Micol V, : Immunoliposome encapsulation increases cytotoxic activity and selectivity of curcumin and resveratrol against HER2 overexpressing human breast cancer cells. Breast Cancer Res Treat 141, 55–65, 2013.
12. Kunwar A, Barik A, Pandey R, and Priyadarsini KI, : Transport of liposomal and albumin loaded curcumin to living cells: an absorption and fluorescence spectroscopic study. Biochim Biophys Acta (BBA)-General Subjects 1760, 1513–1520, 2006.
13. Allen TM, : Liposomes: opportunities in drug delivery. Drugs 54, 8–14, 1997.
14. Lee KD, Nir S, and Papahadjopoulos D, : Quantitative analysis of liposome-cell interactions in vitro: rate constants of binding and endocytosis with suspension and adherent J774 cells and human monocytes. Biochemistry 32, 889–899, 1993.
15. Pandelidou M, Dimas K, Georgopoulos A, Hatziantoniou S, and Demetzos C, : Preparation and characterization of lyophilised EGG PC liposomes incorporating curcumin and evaluation of its activity against colorectal cancer cell lines. J Nanosci Nanotechnol 11, 1259–1266, 2011.
16. Jobin C, Bradham CA, Russo MP, Juma B, Narula AS, et al.: Curcumin blocks cytokine-mediated NF-κB activation and proinflammatory gene expression by inhibiting inhibitory factor I-κB kinase activity. J Immunol 163, 3474–3483, 1999.
17. Zlotogorski A, Dayan A, Dayan D, Chaushu G, Salo T, et al.: Nutraceuticals as new treatment approaches for oral cancer-I: Curcumin. Oral Oncol 49, 187–191, 2013.
18. Li L, Braiteh FS, and Kurzrock R, : Liposome-encapsulated curcumin: in vitro and in vivo effects on proliferation, apoptosis, signaling, and angiogenesis. Cancer 104, 1322–1331, 2005.
19. Khopde SM, Indira Priyadarsini K, Palit DK, and Mukherjee T, : Effect of solvent on the excited-state photophysical properties of curcumin. Photochem Photobiol 72, 625–631, 2000.
20. Wang D, Veena MS, Stevenson K, Tang C, Ho B, et al.: Liposome-encapsulated curcumin suppresses growth of head and neck squamous cell carcinoma in vitro and in xenografts through the inhibition of nuclear factor kappaB by an AKT-independent pathway. Clin Cancer Res 14, 6228–6236, 2008.
21. Saengkrit N, Saesoo S, Srinuanchai W, Phunpee S, and Ruktanonchai UR, : Influence of curcumin-loaded cationic liposome on anticancer activity for cervical cancer therapy. Colloids Surf B Biointerfaces 114, 349–356, 2014.
22. Lu X-Y, Hu S, Jin Y, and Qiu L-Y, : Application of liposome encapsulation technique to improve anti-carcinoma effect of resveratrol. Drug Dev Ind Pharm 38, 314–322, 2012.
23. Neves AR, Martins S, Segundo MA, and Reis S, : Nanoscale delivery of resveratrol towards enhancement of supplements and nutraceuticals. Nutrients 8, 131, 2016.
24. Wang X, Li Y, Yao H, Ju R, Zhang Y, et al.: The use of mitochondrial targeting resveratrol liposomes modified with a dequalinium polyethylene glycol-distearoylphosphatidyl ethanolamine conjugate to induce apoptosis in resistant lung cancer cells. Biomaterials 32, 5673–5687, 2011.
25. Narayanan NK, Nargi D, Randolph C, and Narayanan BA, : Liposome encapsulation of curcumin and resveratrol in combination reduces prostate cancer incidence in PTEN knockout mice. Int J Cancer 125, 1–8, 2009.
26. Mendes D, Alves C, Afonso N, Cardoso F, Passos-Coelho JL, et al.: The benefit of HER2-targeted therapies on overall survival of patients with metastatic HER2-positive breast cancer–a systematic review. Breast Cancer Res 17, 140, 2015.
27. Mignet N, Seguin J, Romano MR, Brullé L, Touil YS, et al.: Development of a liposomal formulation of the natural flavonoid fisetin. Int J Pharm 423, 69–76, 2012.
28. Seguin J, Brullé L, Boyer R, Lu YM, Romano MR, et al.: Liposomal encapsulation of the natural flavonoid fisetin improves bioavailability and antitumor efficacy. Int J Pharm 444, 146–154, 2013.
29. Mousavi SH, Moallem SA, Mehri S, Shahsavand S, Nassirli H, et al.: Improvement of cytotoxic and apoptogenic properties of crocin in cancer cell lines by its nanoliposomal form. Pharm Biol 49, 1039–1045, 2011.
30. Aung H, Wang C, Ni M, Fishbein A, Mehendale S, et al.: Crocin from Crocus sativus possesses significant anti-proliferation effects on human colorectal cancer cells. Exp Oncol 29, 175–180, 2007.
31. Liang T, Guan R, Wang Z, Shen H, Xia Q, et al.: Comparison of anticancer activity and antioxidant activity between cyanidin-3-O-glucoside liposomes and cyanidin-3-O-glucoside in Caco-2 cells in vitro. RSC Adv 7, 37359–37368, 2017.
32. Phan V, Walters J, Brownlow B, and Elbayoumi T, : Enhanced cytotoxicity of optimized liposomal genistein via specific induction of apoptosis in breast, ovarian and prostate carcinomas. J Drug Target 21, 1001–1011, 2013.
33. Halwani M, Hossain Z, Khiyami MA, and Omri A, : Liposomal β-glucan: preparation, characterization and anticancer activities. J Nanomed-Nanotechnol 6, 7, 2015.
34. de Pace RCC, Liu X, Sun M, Nie S, Zhang J, et al.: Anticancer activities of (−)-epigallocatechin-3-gallate encapsulated nanoliposomes in MCF7 breast cancer cells. J Liposome Res 23, 187–196, 2013.
35. Fang J-Y, Lee W-R, Shen S-C, and Huang Y-L, : Effect of liposome encapsulation of tea catechins on their accumulation in basal cell carcinomas. J Dermatol Sci 42, 101–109, 2006.
36. Gharib A, Faezizadeh Z, and Godarzee M, : Preparation and characterization of nanoliposomal beta-cryptoxanthin and its effect on proliferation and apoptosis in human leukemia cell line K562. Trop J Pharm Res 14, 187–194, 2015.
37. Ma X, Zhou J, Zhang C-X, Li X-Y, Li N, et al.: Modulation of drug-resistant membrane and apoptosis proteins of breast cancer stem cells by targeting berberine liposomes. Biomaterials 34, 4452–4465, 2013.
38. Yi C, Fu M, Cao X, Tong S, Zheng Q, et al.: Enhanced oral bioavailability and tissue distribution of a new potential anticancer agent, Flammulina velutipes sterols, through liposomal encapsulation. J Agric Food Chem 61, 5961–5971, 2013.
39. Rodrigues ARO, Mendes PMF, Silva PML, Machado VA, Almeida BG, et al.: Solid and aqueous magnetoliposomes as nanocarriers for a new potential drug active against breast cancer. Colloids Surf B Biointerfaces 158, 460–468, 2017. doi:10.1016/j.colsurfb.2017.07.015.
40. Clares B, Biedma-Ortiz RA, Sáez-Fernández E, Prados JC, Melguizo C, et al.: Nano-engineering of 5-fluorouracil-loaded magnetoliposomes for combined hyperthermia and chemotherapy against colon cancer. Eur J Pharm Biopharm 85, 329–338, 2013.
41. Das AK, Marwal A, and Verma R, : Preparation and characterization of nano-bio hybrid based magneto liposome. Int J Pharm Sci Res 6, 367, 2015.
42. Cardoso BD, Rio IS, Rodrigues ARO, Almeida B, Araújo JP, et al.: Magnetoliposomes Containing Magnesium Ferrite Nanoparticles for Enhanced Therapeutic Potential of Curcumin. Abstract published at NaNaX 8-Nanoscience with Nanocrystals held at Braga, July 3–7, 2017.
43. 2+ by amlodipine thus leading to an enhanced antitumor activity in leukemia. J Control Release 112, 186–198, 2006.
44. Mu L, Ju R, Liu R, Bu Y-Z, Zhang J, et al.: Dual-functional drug liposomes in treatment of resistant cancers. Adv Drug Deliv Rev 115, 46–56, 2017.
45. Li Y, Revalde JL, Reid G, and Paxton JW, : Interactions of dietary phytochemicals with ABC transporters: possible implications for drug disposition and multidrug resistance in cancer. Drug Metab Rev 42, 590–611, 2010.
46. Taur JS, and Rodriguez-Proteau R, : Effects of dietary flavonoids on the transport of cimetidine via P-glycoprotein and cationic transporters in Caco-2 and LLC-PK1 cell models. Xenobiotica 38, 1536–1550, 2008.
47. Satsu H, Hiura Y, Mochizuki K, Hamada M, and Shimizu M, : Activation of pregnane X receptor and induction of MDR1 by dietary phytochemicals. J Agric Food Chem 56, 5366–5373, 2008.
48. Wu C-P, Klokouzas A, Hladky SB, Ambudkar SV, and Barrand MA, : Interactions of mefloquine with ABC proteins, MRP1 (ABCC1) and MRP4 (ABCC4) that are present in human red cell membranes. Biochem Pharmacol 70, 500–510, 2005.
49. Misra R, and Sahoo SK, : Coformulation of doxorubicin and curcumin in poly(D,L-lactide-co-glycolide) nanoparticles suppresses the development of multidrug resistance in K562 cells. Mol Pharm 8, 852–866, 2011.
50. Friberg S, and Nyström AM, : NANOMEDICINE: will it offer possibilities to overcome multiple drug resistance in cancer? J Nanobiotechnology 14, 17, 2016.
51. Sarkar FH, and Li Y, : Harnessing the fruits of nature for the development of multi-targeted cancer therapeutics. Cancer Treat Rev 35, 597–607, 2009.
52. Li Y, and Sarkar FH, : Down-regulation of invasion and angiogenesis-related genes identified by cDNA microarray analysis of PC3 prostate cancer cells treated with genistein. Cancer Lett 186, 157–164, 2002.
53. Meng J, Guo F, Xu H, Liang W, Wang C, et al.: Combination therapy using co-encapsulated resveratrol and paclitaxel in liposomes for drug resistance reversal in breast cancer cells in vivo. Sci Rep 6, 22390, 2016.
54. Imai Y, Tsukahara S, Asada S, and Sugimoto Y, : Phytoestrogens/flavonoids reverse breast cancer resistance protein/ABCG2-mediated multidrug resistance. Cancer Res 64, 4346–4352, 2004.
55. Nabekura T, Yamaki T, Ueno K, and Kitagawa S, : Inhibition of P-glycoprotein and multidrug resistance protein 1 by dietary phytochemicals. Cancer Chemother Pharmacol 62, 867–873, 2008.
56. Zhang Q, Wei D, and Liu J, : In vivo reversal of doxorubicin resistance by (−)-epigallocatechin gallate in a solid human carcinoma xenograft. Cancer Lett 208, 179–186, 2004.
57. Shinkai M, Yanase M, Honda H, Wakabayashi T, Yoshida J, et al.: Intracellular hyperthermia for cancer using magnetite cationic liposomes: in vitro study. Jpn J Cancer Res 87, 1179–1183, 1996.
58. Le B, Shinkai M, Kitade T, Honda H, Yoshida J, et al.: Preparation of tumor-specific magnetoliposomes and their application for hyperthermia. J Chem Eng Japan / JCEJ 34, 66–72, 2001.
59. Shinkai M, Le B, Honda H, Yoshikawa K, Shimizu K, et al.: Targeting hyperthermia for renal cell carcinoma using human MN antigen-specific magnetoliposomes. Jpn J Cancer Res 92, 1138–1146, 2001.
60. Hamaguchi S, Tohnai I, Ito A, Mitsudo K, Shigetomi T, et al.: Selective hyperthermia using magnetoliposomes to target cervical lymph node metastasis in a rabbit tongue tumor model. Cancer Sci 94, 834–839, 2003.
61. Kullberg M, Mann K, and Owens JL, : Improved drug delivery to cancer cells: a method using magnetoliposomes that target epidermal growth factor receptors. Med Hypotheses 64, 468–470, 2005.
62. Zhang JQ, Zhang ZR, Yang H, Tan QY, Qin SR, et al.: Lyophilized paclitaxel magnetoliposomes as a potential drug delivery system for breast carcinoma via parenteral administration: in vitro and in vivo studies. Pharm Res 22, 573–583, 2005.
63. Kikumori T, Kobayashi T, Sawaki M, and Imai T, : Anti-cancer effect of hyperthermia on breast cancer by magnetite nanoparticle-loaded anti-HER2 immunoliposomes. Breast Cancer Res Treat 113, 435–441, 2009.
64. Yoshida M, Watanabe Y, Sato M, Maehara T, Aono H, et al.: Feasibility of chemohyperthermia with docetaxel-embedded magnetoliposomes as minimally invasive local treatment for cancer. Int J Cancer 126, 1955–1965, 2010.
65. Yan C, Wu Y, Feng J, Chen W, Liu X, et al.: Anti-αvβ3 antibody guided three-step pretargeting approach using magnetoliposomes for molecular magnetic resonance imaging of breast cancer angiogenesis. Int J Nanomedicine 8, 245–255, 2013.
66. Yang R, An LY, Miao QF, Li FM, Han Y, et al.: Effective elimination of liver cancer stem-like cells by CD90 antibody targeted thermosensitive magnetoliposomes. Oncotarget 7, 35894–35916, 2016.
67. Khaleghi S, Rahbarizadeh F, Ahmadvand D, and Hosseini HRM, : Anti-HER2 VHH targeted magnetoliposome for intelligent magnetic resonance imaging of breast cancer cells. Cell Mol Bioeng 10, 263–272, 2017.
68. Matos JOG, Rodrigues ARO, Almeida BG, Araújo JP, Castanheira EMS, et al.: Magnetic/Plasmonic MnFe2O4/Au Nanoparticles Covered with Lipid Bilayers for Applications in Thermotherapy. NaNaX 8-Nanoscience with Nanocrystals held at Braga, July 3–7, 2017.
69. Pereira DSM, Rodrigues ARO, Almeida BG, Araújo JP, Machado VA, et al.: Magnetic Liposomes Containing Calcium Ferrite Nanoparticles for Breast Cancer Therapy. NaNaX 8-Nanoscience with Nanocrystals held at Braga, July 3–7, 2017.